Promising Biotech Stocks To Consider – July 18th

Thermo Fisher Scientific, Danaher, AbbVie, Recursion Pharmaceuticals, Vertex Pharmaceuticals, Cognizant Technology Solutions, and IQVIA are the seven Biotech stocks to watch today, according to MarketBeat’s stock screener tool. Biotech stocks are shares of publicly traded companies that use biological research and technology to develop products such as pharmaceuticals, gene therapies, diagnostics and agricultural solutions. Their market value often hinges on lengthy research and development processes, clinical‐trial results and regulatory approvals, making them potentially high‐reward but also high‐risk investments. These companies had the highest dollar trading volume of any Biotech stocks within the last several days.

Thermo Fisher Scientific (TMO)

Thermo Fisher Scientific Inc. provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.

Shares of TMO stock traded down $8.94 during trading hours on Friday, hitting $416.04. 595,722 shares of the company’s stock were exchanged, compared to its average volume of 2,012,621. The stock’s 50-day moving average is $410.13 and its 200-day moving average is $473.73. The company has a debt-to-equity ratio of 0.64, a current ratio of 1.77 and a quick ratio of 1.38. The stock has a market cap of $157.05 billion, a price-to-earnings ratio of 24.42, a price-to-earnings-growth ratio of 2.21 and a beta of 0.77. Thermo Fisher Scientific has a 52 week low of $385.46 and a 52 week high of $627.88.

Danaher (DHR)

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.

Shares of DHR traded down $4.14 during trading hours on Friday, hitting $190.65. 1,274,212 shares of the stock traded hands, compared to its average volume of 3,512,845. The company has a current ratio of 1.43, a quick ratio of 1.05 and a debt-to-equity ratio of 0.31. Danaher has a 1-year low of $171.00 and a 1-year high of $281.70. The firm has a market capitalization of $136.44 billion, a PE ratio of 37.12, a price-to-earnings-growth ratio of 2.71 and a beta of 0.77. The business has a fifty day moving average of $196.12 and a 200-day moving average of $205.48.

AbbVie (ABBV)

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers.

Shares of ABBV traded down $2.06 during trading hours on Friday, hitting $189.34. 1,129,003 shares of the stock traded hands, compared to its average volume of 6,300,692. The company has a current ratio of 0.76, a quick ratio of 0.64 and a debt-to-equity ratio of 44.14. AbbVie has a 1-year low of $163.81 and a 1-year high of $218.66. The firm has a market capitalization of $334.45 billion, a PE ratio of 80.69, a price-to-earnings-growth ratio of 1.26 and a beta of 0.48. The business has a fifty day moving average of $187.07 and a 200-day moving average of $189.30.

Recursion Pharmaceuticals (RXRX)

Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.

Shares of RXRX traded up $0.47 during trading hours on Friday, hitting $5.99. 34,559,755 shares of the stock traded hands, compared to its average volume of 16,975,746. Recursion Pharmaceuticals has a 1-year low of $3.79 and a 1-year high of $12.36. The business has a fifty day moving average of $4.89 and a 200-day moving average of $6.02. The company has a current ratio of 4.11, a quick ratio of 4.11 and a debt-to-equity ratio of 0.02. The firm has a market capitalization of $2.43 billion, a PE ratio of -3.44 and a beta of 0.91.

Vertex Pharmaceuticals (VRTX)

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.

NASDAQ:VRTX traded down $0.11 during mid-day trading on Friday, hitting $463.16. The company had a trading volume of 337,152 shares, compared to its average volume of 1,418,345. Vertex Pharmaceuticals has a fifty-two week low of $377.85 and a fifty-two week high of $519.88. The business’s fifty day moving average is $448.80 and its two-hundred day moving average is $462.07. The company has a debt-to-equity ratio of 0.01, a quick ratio of 2.29 and a current ratio of 2.65. The firm has a market cap of $118.94 billion, a P/E ratio of -118.27 and a beta of 0.41.

Cognizant Technology Solutions (CTSH)

Cognizant Technology Solutions Corporation, a professional services company, provides consulting and technology, and outsourcing services in North America, Europe, and internationally. It operates through four segments: Financial Services, Health Sciences, Products and Resources, and Communications, Media and Technology.

Shares of NASDAQ CTSH traded down $0.15 during mid-day trading on Friday, reaching $75.41. 2,032,965 shares of the company’s stock were exchanged, compared to its average volume of 3,533,143. The firm has a market capitalization of $37.17 billion, a price-to-earnings ratio of 15.88, a PEG ratio of 1.72 and a beta of 0.96. The company has a current ratio of 2.22, a quick ratio of 2.22 and a debt-to-equity ratio of 0.04. The business has a fifty day simple moving average of $79.18 and a 200 day simple moving average of $78.70. Cognizant Technology Solutions has a twelve month low of $65.52 and a twelve month high of $90.82.

IQVIA (IQV)

IQVIA Holdings Inc. engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.

Shares of NYSE IQV traded down $1.91 during mid-day trading on Friday, reaching $161.34. 703,771 shares of the company’s stock were exchanged, compared to its average volume of 1,666,338. The company has a current ratio of 0.82, a quick ratio of 0.82 and a debt-to-equity ratio of 2.19. The firm has a market capitalization of $27.91 billion, a price-to-earnings ratio of 22.00, a PEG ratio of 1.76 and a beta of 1.30. IQVIA has a twelve month low of $134.65 and a twelve month high of $252.88. The business has a fifty day simple moving average of $152.66 and a 200 day simple moving average of $171.09.